Angiotensin-II
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Vasodilatory Shock
Conditions
Vasodilatory Shock
Trial Timeline
Sep 9, 2025 → Jun 1, 2030
NCT ID
NCT07212686About Angiotensin-II
Angiotensin-II is a approved stage product being developed by Innoviva for Vasodilatory Shock. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07212686. Target conditions include Vasodilatory Shock.
Hype Score Breakdown
Clinical
20
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07212686 | Approved | Recruiting |